InfuSystem (NYSE:INFU) Upgraded to Strong-Buy at Sidoti

Sidoti upgraded shares of InfuSystem (NYSE:INFU) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

Separately, StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 14th.

InfuSystem Trading Down 1.2 %

Shares of INFU stock opened at $5.65 on Tuesday. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The firm has a market cap of $118.70 million, a P/E ratio of 94.18 and a beta of 1.75. The company has a 50 day moving average of $7.47 and a 200-day moving average of $7.53. InfuSystem has a 12-month low of $5.29 and a 12-month high of $9.97.

Hedge Funds Weigh In On InfuSystem

Several large investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. boosted its holdings in InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock worth $223,000 after buying an additional 7,295 shares during the period. BNP Paribas Financial Markets lifted its position in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after acquiring an additional 1,626 shares in the last quarter. Barclays PLC boosted its holdings in shares of InfuSystem by 300.5% in the third quarter. Barclays PLC now owns 28,597 shares of the company’s stock worth $192,000 after acquiring an additional 21,457 shares during the period. Geode Capital Management LLC grew its position in shares of InfuSystem by 1.8% in the third quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock valued at $2,925,000 after purchasing an additional 7,550 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of InfuSystem by 74.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock valued at $104,000 after purchasing an additional 6,623 shares during the period. Hedge funds and other institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.